The fate of chemoresistance in triple negative breast cancer (TNBC)

BACKGROUND: Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel (Taxol®). Following chemotherapy, the ideal tumour response is apoptotic cell de...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Reilly, Elma A., Gubbins, Luke, Sharma, Shiva, Tully, Riona, Guang, Matthew Ho Zhing, Weiner-Gorzel, Karolina, McCaffrey, John, Harrison, Michele, Furlong, Fiona, Kell, Malcolm, McCann, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661576/
https://www.ncbi.nlm.nih.gov/pubmed/26676166
http://dx.doi.org/10.1016/j.bbacli.2015.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661576/
https://www.ncbi.nlm.nih.gov/pubmed/26676166
http://dx.doi.org/10.1016/j.bbacli.2015.03.003

Ejemplares similares